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Abstract
We evaluated the cost-effectiveness of rotavirus vaccination in Uzbekistan from the 
healthcare system and societal perspectives. Disease burden was estimated using national 
statistics on hospitalizations and deaths, and international estimates of under-five mortality. 
Without vaccination, the risk for rotavirus hospitalization by age 5 is 10 per 1000 children. 
Rotavirus hospitalizations cost US$ 406,000 annually, of which US$ 360,000 (89%) is for 
medical expenses and US$ 46,000 (11%) is for non-medical and indirect costs. Rotavirus 
mortality rate at 0.7 per 1000 derived from national data was three-fold lower than the same 
rate calculated from international estimates of under-five mortality. Rotavirus vaccination 
could reduce hospitalizations and deaths by 91% and avert US$ 370,000 in hospitalization 
costs alone. Vaccination would be cost-effective with vaccine prices in a range of US$ 2–25 
per child. However, the cost-effectiveness is greatly influenced by mortality, vaccine price 
and vaccine efficacy.
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bstract
We evaluated the cost-effectiveness of rotavirus vaccination in Uzbekistan from the healthcare system and societal perspectives. Disease
urden was estimated using national statistics on hospitalizations and deaths, and international estimates of under-five mortality. Without
accination, the risk for rotavirus hospitalization by age 5 is 10 per 1000 children. Rotavirus hospitalizations cost US$ 406,000 annually, of
hich US$ 360,000 (89%) is for medical expenses and US$ 46,000 (11%) is for non-medical and indirect costs. Rotavirus mortality rate at 0.7
er 1000 derived from national data was three-fold lower than the same rate calculated from international estimates of under-five mortality.
otavirus vaccination could reduce hospitalizations and deaths by 91% and avert US$ 370,000 in hospitalization costs alone. Vaccination
ould be cost-effective with vaccine prices in a range of US$ 2–25 per child. However, the cost-effectiveness is greatly influenced by mortality,
accine price and vaccine efficacy.
2006 Elsevier Ltd. All rights reserved.
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. Introduction
Rotavirus is the most common cause of severe diarrhea
mong children <5 years of age, and is responsible for sub-
tantial mortality and morbidity, particularly in countries with
ow income [1,2]. Currently, vaccines against rotavirus are
he principle strategy to reduce the disease burden worldwide
3,4], and the universal vaccination could decrease medical
nd societal costs of disease. While the economic impact of
isease and the cost-effectiveness of vaccination have been
 The findings and conclusions in this report are those of the authors and
o not necessarily represent the views of the RVP, GAVI, or The Vaccine
und.
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oi:10.1016/j.vaccine.2006.07.029ssessed in industrialized countries [5,6], few data are avail-
ble for countries with low income [7,8]. When considering
n introduction of a new vaccine, national estimates of dis-
ase and economic burden and of the cost-effectiveness of
accination are needed [9].
In the Newly Independent States of the former Soviet
nion, a few studies on rotavirus disease were conducted
reviously [10–12] but the disease burden remains uncer-
ain in Uzbekistan, a country in Central Asia. With a
003 per capita gross domestic product (GDP) of US$ 389
13], the country is eligible for funding from the Global
lliance for Vaccines and Immunization (GAVI) to pur-
hase new vaccines. Uzbekistan already has high vaccine
overage (98%) [14] and a mature and stable infrastruc-
ure to deliver vaccines. With support from the GAVI,
zbekistan recently introduced hepatitis B vaccine, and
ould be an early adopter of new rotavirus vaccines as
ell.
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To facilitate decisions about the introduction of rotavirus
accines, we conducted active surveillance for rotavirus dis-
ase in a large pediatric hospital in 2003–2004. We also
erformed an economic study to determine the medical and
ocietal costs of disease in order to estimate the economic
urden and project the cost-effectiveness of vaccination. Both
tudies were based on the World Health Organization (WHO)
eneric protocols [15,16], which for the first time assessed
he national rotavirus disease and economic burden in a Cen-
ral Asian country, eligible for international assistance for
accine introduction.
. Methods
.1. Health care and societal costs
In the economic study, we collected data on healthcare
osts from families of 84 children hospitalized with diarrhea
n June–July 2004 at two hospitals: the Tashkent Children’s
ospital, a tertiary hospital in the capital city in the east,
nd the Bukhara Regional Hospital, a secondary hospital in
he west. Children aged 1–59 months hospitalized within 7
ays of the onset of acute diarrhea, defined by the admitting
hysician, were eligible for enrollment. Written informed
onsent was obtained from parents or guardians prior to
nrollment. Hospital surveillance for rotavirus was conducted
n the Tashkent Hospital in 2003–2004 using the same enroll-
ent criteria.
Data on direct medical costs of hospitalizations, i.e. the
umber and type of diagnostic procedures performed, the
uantity of drugs and supplies used, and the length of hospital
tay, were extracted from medical records of each child. Unit
osts of the hospital bed day, medications, and diagnostics
ere obtained from national price lists and hospital invoices.
espite the free health care system, families of patients often
ay fees to health care workers and purchase additional med-
cations and supplies; these expenses were added to the direct
edical costs. Data on non-medical and indirect costs were
ollected by trained study personnel who administered a
uestionnaire to parents or caregivers during face-to-face
nterviews. Direct non-medical costs were defined as the
osts of food and transportation to and from the hospital that
ncurred as a result of this illness prior to and during hospital-
zation. Indirect or societal costs were defined as income lost
y caregivers due to this illness and were calculated by mul-
iplying the mean hourly wage reported by caregivers by the
umber of hours lost from paid work. All local currency costs
ere converted into US dollars using the 2004 exchange rate
1020 sums per US$) of the National Bank of Uzbekistan.
.2. National disease and economic burdenTo estimate the national disease and economic burden
f rotavirus diarrhea, we developed a model to calculate
umbers of rotavirus hospitalizations and deaths that would
m
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ccur without and with vaccination for the 2004 birth cohort
n = 538,128) followed for first 5 years of life. The number
f rotavirus hospitalizations was estimated by multiplying
he number of diarrhea hospitalizations among children <5
ears of age by 27%, a proportion of diarrhea hospitalizations
ttributable to rotavirus established in the surveillance study.
otavirus mortality was estimated using the under-five mor-
ality rates derived from international reports [17] and from
ational data submitted by the country to the WHO [18]. We
hen applied the 17% fraction of deaths attributable to diar-
hea in countries with low-middle income [1] to estimates of
nder-five mortality to obtain total number of diarrhea deaths.
higher fraction of 21% estimated for countries with low
ncome was not used because Uzbekistan has a developed
ealthcare system with a good access to services, and the use
f a higher fraction might overestimate the true mortality.
umber of rotavirus deaths was calculated by multiplying
he number of diarrhea deaths in children <5 years by 20%,
he fraction of diarrhea deaths attributable to rotavirus esti-
ated previously [1]. Less severe rotavirus disease outcomes,
ncluding outpatient visits or community-based disease, were
ot included in the model because incidence of these out-
omes was not available.
The economic burden was estimated by multiplying the
ean costs per child by the expected number of cases and
eaths. The health burden of rotavirus diarrhea was also esti-
ated in terms of disability-adjusted life years (DALYs) [19].
ALYs quantify the years lost due to premature mortality and
he years lived with disability, allowing for comparisons with
ther diseases. The DALY loss from mortality was calculated
n the basis of the standardized life expectancy of 65.5 years
or children less than 1-year-old in Uzbekistan. The DALY
oss from all symptomatic cases was calculated on the basis
f default disability weights, and an estimated duration of
otavirus illness of 6 days [20]. Estimates were discounted
t a rate of 3% and weighted by age to ensure comparability
21].
.3. Vaccine characteristics
To estimate the impact of a vaccination program on the
isease burden, we combined vaccine efficacy and cover-
ge as variable functions dependent on age. Vaccine efficacy
or prevention of both rotavirus hospitalizations and deaths
as 93% based upon results of clinical trials [22]. Since the
accine will be incorporated into the current immunization
chedule to coincide with the administration of the first two
oses of diphtheria–tetanus toxoids–pertussis vaccine (DTP),
e used the DTP-3 vaccine coverage rate of 98% at 1 year
f age in Uzbekistan [14] as a proxy for rotavirus vaccina-
ion coverage. The model assumed on-time immunization of
two-dose oral vaccine at ages 2 and 4 months. Since the
arket price of vaccine was unknown at the time of analysis,
range of prices (US$ 2–25 per course) was used. Based on
revious estimates [23–26], we assumed a low incremental
ost of US$ 0.25 for oral administration of rotavirus vaccine.
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Table 1
Comparison of patients enrolled in the rotavirus surveillance study and patients enrolled in the economic study in Uzbekistan, 2003–2004
Characteristics Patients enrolled in
Hospital surveillance Economic study
No rotavirus (n = 520) % (n) With rotavirus (n = 196) % (n) (n = 84) % (n)
Age group (months)
0–2 1 (3) 0 7 (6)
3–5 17 (87) 6 (11) 21 (18)
6–8 19 (98) 15 (29) 18 (15)
9–11 16 (81) 13 (25) 15 (13)
12–23 26 (137) 29 (57) 23 (19)
24–35 12 (65) 20 (40) 8 (7)
36–47 7 (36) 9 (18) 5 (4)
48–59 2 (13) 8 (16) 3 (2)
Sex
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and 3% (2) visited a traditional healer. No patient received
more than a single point of care prior to being admitted to the
hospital. The median distance from a child’s home to the hos-
pital was 10 km (range, 1–100 km) and most caregivers (96%)
Table 2
Types of medical care sought by 84 diarrhea patients before hospitalization
and sources of funds used by caregivers for out-of-pocket expenditures,
Uzbekistan 2004
Variable % (n)
Type of medical care before hospitalization
Outpatient clinic 60 (51)
Private physician 10 (9)
Another hospital 4 (3)
Pharmacy 4 (3)
Traditional healer 3 (2)
No care 19 (16)
Means of transport to hospitala
Personal car 33 (28)
Ambulance 32 (27)
Taxi 25 (21)
Public transport 11 (9)
By foot 4 (3)
Distance (km) to hospital, median (range) 10 (1–100)
Caregiver trips per day per family to hospital,
mean (S.D.)
2.3 (1)
Sources of fundsb
Savings 73 (61)
Loan from relatives or friends 20 (17)
Reduction in other expenses 17 (14)
Sale of assets 1 (1)
Monthly household income (2004 $), mean
(S.D.)c
70 (44)
Children per household, median (range) 2 (1–7)
Adults per household, median (range) 4 (2–12)
a Four caregivers reported using more than one type of transport.Male 52 (272)
Female 48 (248)
Length of stay (days), mean (range) 6.2 (1–19)
.4. Cost-effectiveness and sensitivity analyses
The cost-effectiveness analysis was performed from the
ealthcare system and societal perspectives. We calculated
he incremental cost-effectiveness ratio (ICER) expressed as
he cost per DALY averted and as the cost per life saved. The
CER is the net cost (costs of administering the rotavirus
accine minus the medical costs averted by vaccination)
ivided by the DALYs or deaths averted by vaccination. The
ost-effectiveness ratio was calculated for a range of vac-
ine prices. The WHO’s World Health Report suggests that
nterventions with a ICER (in $/DALY) of less than the per
apita GDP should be considered “very cost-effective” and
hose with an ICER less than three times the GDP should
e considered “cost-effective” [27]. We performed one-way
ensitivity analyses to assess the impact of high and low esti-
ates of rotavirus mortality and hospitalization rates, vaccine
fficacy, and vaccine price on the cost-effectiveness ratios.
. Results
.1. Health care and societal costs
Of 84 children enrolled in the economic study, 43 (51%)
ere treated in the Tashkent Hospital and 41 (49%) in the
ukhara Hospital. Of the 716 children enrolled in rotavirus
urveillance, 27% (196) had rotavirus detected in stools. No
ifferences were observed between children with and with-
ut rotavirus diarrhea (Table 1). Therefore, estimates of costs
ncurred in treating patients enrolled in the economic study
hould be representative of costs incurred in treating rotavirus
atients. Of the 84 patients in the economic study, 81% (68)
ought medical care prior to being admitted to the hospital
Table 2). Of these 68 patients, 75% (51) attended an out-
atient facility, 13% (9) visited a private physician, 4% (3)
ought care in another hospital, 4% (3) went to a pharmacy,
o
B
o
59 (115) 67 (56)
41 (81) 33 (28)
6.8 (1–17) 6.8 (1–12)b Nine caregivers reported using more than one source of funds to cover
ut-of-pocket expenses.
c The 2004 exchange rate of US$ 1.00 = 1020 Sums is applied (the National
ank of Uzbekistan, Interstate Statistical Committee of the Commonwealth
f Independent States).
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Table 3
Frequency and costs of diagnostic procedures in 2004 US dollarsa incurred during hospitalizations of 84 children with acute diarrhea, Uzbekistan
Diagnostic procedures Subjects undergoing procedures,
% (n)
Procedures per subject, mean
(range)
Unit cost per
test, US$
Cost US$ per subject,
mean (S.D.)b,
For the child
Blood cells count 100 (84) 1.5 (1–3) 0.37 0.60 (0.20)
Blood culture 15 (13) 1.0 (1–2) 2.50 0.42 (1.03)
Stool microscopy 100 (84) 2.3 (1–5) 0.37 0.90 (0.50)
Stool culture 99 (83) 2 (1–3) 7.50 15 (7.50)
Cholera testc 100 (84) 1 (1–1) 6.30 3 (0.00)
Urine test 100 (84) 1.5 (1–3) 0.32 0.50 (0.22)
HBsAgd 51 (43) 1 (1–2) 0.22 0.12 (0.12)
Blood protein 14 (12) 1 (1–2) 0.10 0.02 (0.04)
For the guardiane
Syphilis test 51 (43) 1 (0–1) 0.45 0.23 ± 0.22
Total diagnostics cost 21 ± 7.10
a The 2004 exchange rate of US$ 1.00 = 1020 sums is applied (the National Bank of Uzbekistan, Interstate Statistical Committee of the Commonwealth of
Independent States).
b Diagnostics cost = unit cost of procedure × mean number of procedures performed × proportion of children undergoing test. S.D., standard deviation.
c The cost of cholera test per child was adjusted because the test is performed only during 5 months of each year, i.e., from May through September.
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risk for hospitalization due to rotavirus disease is 10 per 1000
resulting in 1 child in every 100 being hospitalized by age 5.
We estimated the annual costs of rotavirus hospitalizations
to be US$ 406,358, of which US$ 361,738 (89%) are direct
Table 4
Costs in 2004 US dollars incurred in treating 84 children with acute diarrhea,
Uzbekistan
Cost category Cost per episode,
mean (S.D.)
Direct medical costs
Pre-hospitalization carea (medicines and
physician’s fee)
2.0 (4)
Diagnostics 21.0 (7)
Medicines 9.4 (29)
Bed and foodb 21.2 (26)
Physician’s feea 3.2 (3)
Non-hospital medicinesa 12.5 (15)
Total 69.3 (13)
Direct non-medical costsa
Transportation 2.0 (2)
Food for caregiver 6.2 (7)
Total 8.2 (4)
Indirect costs
Percent of caregivers who lost paid work 29
Hours of work lost, mean (S.D.) 3 (9.0)
Mean hourly wagec 0.40
Total 0.35
Total direct and indirect cost per episode 77.8 ± 13.5d HBsAg denotes hepatitis B surface antigen.
e Mothers or guardians who are commonly hospitalized together with chil
f Health.
eported paying for their transportation. The main source of
unds used by the families to cover costs of hospitalization
as savings (73%), but others reported taking a loan from
elatives or friends (20%), reducing other expenses (17%), or
elling assets (1%).
The average cost of a routine diagnostic work-up for a
hild with diarrhea was US$ 21. The routine evaluation per
urrent treatment protocol included a blood cell count, a
hemical urinalysis, a test for hepatitis B surface antigen,
t least two mandatory stool cultures for Salmonella and
higella organisms, a latex agglutination test for cholera,
nd stool microscopy for blood and proteins (Table 3). In
zbekistan, parents or guardians commonly stay in hospital
ogether with young children and at the Tashkent Hospital,
hese adults also underwent obligatory testing for syphilis.
uch extensive diagnostic work-ups including frequent cul-
ures and testing for cholera (and syphilis in adults) are part
f the standard protocol for infectious disease surveillance.
he total average cost per hospitalized child with diarrhea
as US$ 77.80 (Table 4). Direct medical costs accounted
or 89% of this total, while non-medical costs constituted
0.5% and indirect costs 0.5%. Of direct medical expenses
er hospitalized child, the health care system incurred 75%
f the costs and the patient’s family covered the remaining
5%. Only 29% of parents incurred indirect medical costs by
osing time from paid work due to a child’s illness.
.2. National disease and economic burden
Based on nationally reported hospitalizations for diarrhea
n children <5 years old in 2004 (n = 19,511), and on the
004 birth cohort (n = 538,128), the estimated cumulative
isk for a child to be hospitalized for diarrhea by age 5 is 36.3
er 1000 children. Since 27% of diarrhea hospitalizations in
6
2
dergo mandatory testing for syphilis per the current protocol of the Ministry
he surveillance study were attributable to rotavirus, approx-
mately 5300 children would be hospitalized for rotavirus
iarrhea annually without vaccination. Thus, the cumulativea Expenses covered by caregivers.
b Includes a bed day cost of hospitalization ($/day) for a mean duration of
.8 days.
c Mean hourly wage is calculated for a mean monthly income assuming
2 working days of 8 h/day.
E.T. Isakbaeva et al. / Vaccin
Table 5
Mortality estimates in children under 5 years of age in Uzbekistan based on
data from national and international reports, 2004
Events National estimatesa International estimatesb
Rate per 1000 No. Rate per 1000 No.
All deaths 21 11355 68.6 36915
Diarrhea deaths 3.6 1930 12 6275
Rotavirus deaths 0.7 387 2.3 1255
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a Source: World Health Organization (WHO). WHO Regional Office for
urope, Copenhagen, Denmark. European health for all database.
b Source: World Bank. World Development Indicators Online 2005.
edical costs and US$ 44,620 (11%) are non-medical and
ndirect costs. This does not include the costs associated with
utpatient visits or home care.
In 2004, the under-five mortality rate calculated from the
ational data was 21 per 1000 [18], equivalent to 11,355
nnual deaths. If 17% of these deaths in children <5 years
re due to diarrhea, the expected diarrhea mortality rate is
.6 per 1000 children. If rotavirus is responsible for 20% of
ll diarrhea deaths [1], approximately 400 rotavirus deaths
ould occur annually or 1 death in every 1400 children by
ge 5 (Table 5). However, the under-five mortality rate in 2004
stimated for Uzbekistan by the World Bank and the UNICEF
17] was 68.6 per 1000 children, equivalent to 36,915 annual
b
f
w
t
able 6
stimates of rotavirus disease burden based on national data, and estimates of econ
or the 2004 birth cohorta
ariable No vaccination
vents
Deaths 387 (1255)
Hospitalizations 5268
DALYs 12894 (41445)
ospitalization costs, 2004 US$
Direct medical 361738
Direct non-medical 42793
Indirect 1827
Total 406358
ntervention cost, 2004 US$b
Vaccination cost per course
2 –
5 –
10 –
20
ncremental cost-effectiveness ratio
$/DALY averted, 2004 US$
2 –
5 –
10 –
20 –
$/Life saved, 2004 US$
2 –
5 –
10 –
20 –
a Disease burden estimates derived from international data on under-five mortalit
b Intervention cost includes vaccine price and vaccine administration cost.e 25 (2007) 373–380 377
eaths. By applying this rate and repeating the above calcula-
ions, we obtained 1255 rotavirus deaths annually, equivalent
o 1 child in every 400 dying from rotavirus by age 5. Thus,
he rotavirus mortality rate at 2.3 per 1000 derived from inter-
ational estimates is three-fold greater than the same rate at
.7 per 1000 calculated from the national data. The consider-
ble range between the two rates is because of use of different
stimates of under-five mortality, which is impossible to rec-
ncile with currently available data.
.3. Cost-effectiveness analysis
With the current level of routine coverage (98%) [14] and
accine efficacy of 93% [22], an on-time rotavirus immuniza-
ion program in Uzbekistan is projected to prevent annually
1% (4801) of hospitalizations in children <5 years of age. Of
he total costs of rotavirus hospitalizations of US$ 406,000,
he government pays ∼90% per year. By preventing hospi-
alizations, the vaccine program would save US$ 328,154
n direct medical expenses and an additional US$ 40,667 in
irect non-medical and indirect costs (Table 6). The num-
er of rotavirus deaths averted by vaccination would range
rom approximately 350 to 1150 deaths annually depending
hether the mortality rate based on national data or interna-
ional estimates is applied. At a vaccine price of US$ 2 per
omic burden and cost-effectiveness of rotavirus vaccination in Uzbekistan
With vaccination Averted by vaccination
34 (111) 353 (1144)
467 4801
1174 (3704) 11720 (37741)
33584 328154
3791 39002
162 1665
37538 368820
1423887 –
3164193 –
6064703 –
11865722
94 (29) –
242 (75) –
489 (152) –
984 (306) –
3103 (958) –
8031 (2479) –
16245 (5015) –
32673 (10087) –
y are provided in parentheses for comparison.
378 E.T. Isakbaeva et al. / Vaccin
Table 7
Sensitivity analysis of rotavirus vaccination in Uzbekistan
Variable Value % Change Cost-effectiveness
ratio
% Change
in ICER
Rotavirus mortality/1000
Low 0.4 −50 971 +99
Baselinea 0.7 489
High 1.1 +50 327 −33
Vaccine price per course, US$
Low 5 −50 242 −51
Baseline 10 489
High 15 +50 737 +51
Rotavirus hospitalizations/1000
Low 7.3 −25 118 +1
Baseline 9.8 117
High 12.2 +25 115 −1
Efficacy against rotavirus mortality
Low 80 −14 135 +16
Baseline 93 117
High 100 +8 108 −7
Efficacy against rotavirus hospitalizations
Low 80 −14 117.4 +1
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Baseline 93 116.5
High 100 +8 116 0
a Rotavirus mortality rate derived from national data is the baseline.
ourse, a vaccination program would cost US$ 1.4 million
nd could avert more than US$ 328,000 in direct medical
osts and US$ 41,000 in non-medical and indirect costs.
ased on the World Health Report’s standard for “very cost-
ffective” interventions [27], rotavirus vaccination would be
very cost-effective” at vaccine prices up to US$ 8 per child
f the mortality rate based on national data is used. How-
ver, when another rate derived from international estimates
s applied, the vaccination would be “very cost-effective”
ven at vaccine prices up to US$ 25 per child.
Therefore, the variability in mortality estimates and the
accine price have the largest impact on the cost-effectiveness
atio, which is also demonstrated by the sensitivity analy-
is (Table 7). Raising the mortality rate calculated from the
ational estimates at 0.7 per 1000 by 50% provided a 33%
ecrease in the ICER from the baseline value, whereas low-
ring the rotavirus mortality rate by 50% resulted in almost
00% increase in the ICER. Vaccine prices of US$ 5 and
5 per course resulted in an ICER of US$ 242 and 737 per
ALY, respectively, corresponding to a 51% change in the
CER. However, adjusting the rotavirus hospitalization rate
y 25% (from 9.8 to 12.2 per 1000 children) resulted only
n a 1% change in the ICER. Similarly, adjusting the vaccine
fficacy against mortality had a greater impact on the ICER
ompared to changing the efficacy against hospitalizations.. Discussion
We examined costs of rotavirus diarrhea from the
ealthcare and societal perspectives and projected cost-
t
q
w
e 25 (2007) 373–380
ffectiveness of universal rotavirus immunization in Uzbek-
stan. This study has quantified for the first time the disease
nd economic burden of rotavirus in an ex-Soviet country in
entral Asia, using the limited available data on childhood
ospitalizations and deaths. Without vaccination, rotavirus
isease is estimated to cause 5300 hospitalizations annually
n children <5 years of age. The immunization program when
accine was delivered on schedule could prevent 91% of these
ospitalizations and produce a saving of US$ 368,829 in hos-
italization costs alone. The cost-effectiveness of vaccination
rogram is greatly influenced by rotavirus mortality, followed
y vaccine price and efficacy. Estimates derived in our study
emonstrated a considerable range between mortality rates
alculated from national and international sources of data.
ince Uzbekistan has an established healthcare system with
good access to services and high vaccine coverage, the inter-
ational estimates of under-five mortality might be too high.
oreover, these are generalized estimates based on extrapo-
ations from household surveys and censuses [17], which may
ot be entirely representative of the country. Alternatively, the
ational statistics demonstrate very few under-five deaths but
t probably does not reflect the true mortality either because
f high under-registration of deaths and uncertainty in coding
f underlying causes [18]. By comparison, the 2004 under-
ve mortality rate calculated from national data in Kyrgyz
epublic, a country neighboring Uzbekistan, is almost two
imes higher than the same rate obtained from Uzbek national
tatistics [18]. Since two countries have similar income and
ealthcare systems, projections of rotavirus mortality based
n the Uzbek national data may be an underestimation. The
ange between different estimates of under-five mortality
akes difficult to examine the true burden of rotavirus disease
nd accurately assess the cost-effectiveness of vaccination. In
act, the difference between estimates derived from national
nd international reports makes us doubt the credibility of
ither source and emphasizes the need for reliable data on
hildhood mortality in low-income countries.
Nevertheless, our analysis demonstrated that rotavirus
accination program would be cost-effective with vaccine
rices in a range of US$ 2–25 per child depending on which
ortality rate is applied. If estimates from national data are
sed, the intervention would by far less cost-effective com-
ared to that with the use of international estimates. Universal
accination at a vaccine price of US$ 25 per child would cost
n additional US$ 15 million to the national immunization
rogram. That said, most of vaccines used in the Expanded
rogram on Immunization in Uzbekistan are currently pur-
hased at a UNICEF’s average weighted price of US$ 1 per
hild [28]. Hence, while the US$ 25 price per course might be
onsidered cost-effective in global economic terms, it would
ramatically increase vaccine purchase costs in Uzbekistan
nd would not be sustainable.Hospitalization costs in our study were mainly driven by
he costs of diagnostics and the length of hospital stay. Fre-
uent culturing and prolonged hospitalizations of patients
ith infectious diseases are a common practice in former
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oviet countries, resulting in inflated medical costs due
o mandatory testing of patients with diarrhea for cholera,
almonella and Shigella, and their caregivers for syphilis. If
he routine work-up included only one stool culture per child
nd excluded tests for cholera and syphilis, the medical costs
f hospitalization could be reduced by nearly 20% without
ny appreciable loss in quality of delivered care. Shorten-
ng the hospital stay would further decrease hospitalization
osts. Thus, amending the routine diarrhea treatment protocol
ould be an important cost-saving strategy for a country with
imited resources. However, the reduction in costs yielded
y rotavirus vaccination would be greater and merely limit-
ng unnecessary diagnostic evaluations would slightly reduce
nly the economic burden of rotavirus disease and have little
mpact on the cost-effectiveness of vaccination.
In our analysis, families of patients with diarrhea incurred
ne-third of total hospitalization costs and covered one-fourth
f all direct medical costs by out-of-pocket expenditures.
he out-of-pocket expenses represented 37% of the mean
ousehold income per month, demonstrating the substantial
conomic burden incurred by families. These estimates do
ot include costs associated with outpatient visits and likely
nderestimate the total burden. The introduction of routine
otavirus vaccination and use of amended diagnostic and
reatment protocols might limit family-borne costs signifi-
antly.
We found low societal costs of disease because few par-
nts reported salary loss, most of whom were women who
arn less than men or traditionally stay home. Thus, our
stimates may not be representative of other low-income
ountries where women earn income, which is a limitation of
he study. Among other limitations, we used the local costs
f the hospital bed day to estimate medical costs of hospi-
alizations. By comparison, had we used the standard WHO-
HOICE (CHOosing Interventions that are Cost Effective)
roject estimates for bed day costs [29] that were 28% higher,
he economic burden of rotavirus hospitalization costs would
e greater, making rotavirus vaccination slightly more cost-
ffective. However, country-specific estimates may be more
recise than estimates obtained by generic methods, such
s WHO-CHOICE, and therefore may be closer to the true
osts. We did not include costs incurred by outpatient vis-
ts or less severe rotavirus cases because incidence rates of
hese outcomes and their costs were unavailable. Excluding
hese events that are more common but not captured by the
ealth care system underestimates the actual disease and eco-
omic burden of rotavirus and reduces the beneficial impact
f vaccination. Lastly, we assumed that implementation costs
f rotavirus immunization were low, based on limited pub-
ished data. If additional resources were required to introduce
his new vaccine, the costs of the vaccination program would
e higher.Introducing new rotavirus vaccines in Uzbekistan could be
n effective intervention because it would reduce the disease
utcomes and associated health care costs. However, the abil-
ty of a country to introduce the vaccine and sustain its use will
[
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e more influenced by price than merely by cost-effectiveness
stimates. To better define the disease and economic burden
f rotavirus, our analysis should be expanded to include reli-
ble estimates on childhood mortality, data on other disease
utcomes, and cost estimates that reflect expenses in smaller
ospitals and outpatient facilities. Similar analyses should be
epeated in other countries to assess the need for new rotavirus
accines.
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